PURPOSE To explore the efficacy and safety of the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Osimertinib in the treatment of patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer (NSCLC). METHODS The clinical data of 84 patients with advanced NSCLC treated in our hospital from September 2016 to March 2018 were retrospectively analyzed. All patients had progressive disease (PD) after treatment with first-generation EGFR-TKI, and then they were treated with Osimertinib. The remission of disease was analyzed and evaluated after treatment, and the long-term survival and progression of disease were recorded via follow-up. The influencing factors for the patient's prognosis were explored using univariate and multivariate Cox regression analyses. RESULTS The efficacy was evaluated in all patients at 4 weeks after treatment. There were 0 cases of complete response (CR), 34 cases (40.5%) of partial response (PR), 38 cases (45.2%) of stable disease (SD) and 12 cases (14.3%) of PD. The objective response rate (ORR) and the disease control rate (DCR) were 40.5% (34/84) and 85.7% (72/84), respectively. The main adverse reactions included diarrhea (34.5%), nausea and vomiting (14.3%), constipation (11.9%), rash (27.4%), skin itch (20.2%), loss of appetite (13.1%), oral ulcer (10.7%), hepatic dysfunction (2.4%) and bone marrow suppression, mostly of grade I-II, which could be significantly relieved after symptomatic treatment. The incidence rate of grade III and above adverse reactions was 9.5% (8/84). The dosage of Osimertinib was reduced in 2 cases due to adverse reactions, while other adverse reactions were improved after symptomatic treatment. The levels of vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) obviously declined from 247.57±20.72 pg/mL and 11.20±1.38 μg/L before treatment to 134.84±14.37 pg/mL and 6.80±0.54 μg/L after treatment (p<0.05). The median overall survival (mOS) and median progression-free survival (mPFS) were 25.3 and 10.6 months, respectively. The 1-year OS rate was 79.8% (67/84), and the OS rate was 52.3% at the end of follow-up. Subgroup analysis showed found that heart disease and thrombosis complicated before treatment had significant impact on mOS (p=0.007, p=0.019). The results of multivariate Cox regression analysis revealed that heart disease and thrombosis complicated before treatment were independent risk factors affecting the patient's OS [HR=2.339 (95% CI: 1.448-5.674), p=0.031, HR=1.977 (95% CI: 1.152-2.365), p=0.020]. CONCLUSION Osimertinib has definite efficacy in the treatment of patients with first-generation EGFR-TKI-resistant advanced NSCLC, with a low incidence rate of tolerable adverse reactions. The presence or absence of heart disease and thrombosis before treatment are independent influencing factors for the patient OS.
The Editors of JBUON issue an Expression of Concern to 'Myricetin exhibits anti-glioma potential by inducing mitochondrial-mediated apoptosis, cell cycle arrest, inhibition of cell migration and ROS generation', by Hu-Guang Li, Jun-Xia Chen, Jun-Hui Xiong, Jin-Wei Zhu, JBUON 2016;21(1):182-190; PMID:27061547. Following the publication of the above article, readers drew to our attention that part of the data was possibly unreliable. We sent emails to the authors with a request to provide the raw data to prove the originality, but received no reply. Therefore, as we continue to work through the issues raised, we advise readers to interpret the information presented in the article with due caution. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
The Editors of JBUON issue an Expression of Concern to 'Swerchirin Boswellic acid exerts potent anticancer effects in HCT-116 human colon cancer cells mediated via induction of apoptosis, cell cycle arrest, cell migration inhibition and inhibition of PI3K/AKT signalling pathway', by Dan Wang, Shuke Ge, Jichang Bai, Yongwei Song, JBUON 2018;23(2):340-345; PMID:29745074. Following the publication of the above article, readers drew to our attention that part of the data was possibly unreliable. We sent emails to the authors with a request to provide the raw data to prove the originality, but received no reply. Therefore, as we continue to work through the issues raised, we advise readers to interpret the information presented in the article with due caution. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
The Editors of JBUON issue an Expression of Concern to 'Baicalein suppresses the growth of the human thyroid cancer cells by inducing mitotic catastrophe, apoptosis and autophagy via NF-kB signalling pathway', by Shijian Yi, Guowen Liu, Yang Wu, Qiankun Liang, Lanlan Li; JBUON 2020;25(1):389-394; PMID: 32277659. Following the publication of the above article, readers drew to our attention that part of the data was possibly unreliable. We sent emails to the authors with a request to provide the raw data to prove the originality, but received no reply. Therefore, as we continue to work through the issues raised, we advise readers to interpret the information presented in the article with due caution. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
The Editors of JBUON issue an Expression of Concern to 'The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/βcatenin signalling pathway', by Bin Chen, Tao He, Li Wu, Ting Cao, Hongmei Zheng; JBUON 2020;25(1):421-426; PMID: 32277664. Following the publication of the above article, readers drew to our attention that part of the data was possibly unreliable. We sent emails to the authors with a request to provide the raw data to prove the originality, but received no reply. Therefore, as we continue to work through the issues raised, we advise readers to interpret the information presented in the article with due caution. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
The Editors of JBUON issue an Expression of Concern to 'Antiproliferative potential of piperine and curcumin in drug-resistant human leukemia cancer cells are mediated via autophagy and apoptosis induction, S-phase cell cycle arrest and inhibition of cell invasion and migration', by Ning Li, Shuyun Wen, Guohua Chen, Shijun Wang; JBUON 2020;25(1):401-406; PMID: 32277661. Following the publication of the above article, readers drew to our attention that part of the data was possibly unreliable. We sent emails to the authors with a request to provide the raw data to prove the originality, but received no reply. Therefore, as we continue to work through the issues raised, we advise readers to interpret the information presented in the article with due caution. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
The Editors of JBUON issue an Expression of Concern to ' Kutkoside-an iridoid glycoside, exerts anti-proliferative effects in drug-resistant human oral carcinoma cells by targeting PI3K/AKT signalling pathway, inducing apoptosis and suppressing cell migration and invasion', by Jun-Chi Hou, Xiao-Nan Xu, JBUON 2020;25(1):338-343; PMID: 32277652. Following the publication of the above article, readers drew to our attention that part of the data was possibly unreliable. We sent emails to the authors with a request to provide the raw data to prove the originality, but received no reply. Therefore, as we continue to work through the issues raised, we advise readers to interpret the information presented in the article with due caution. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
